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Background: Dopaminergic (DA) neurons in the ventral midbrain selectively degenerate in Parkinson’s disease (PD)
in part because their oxidative environment in the substantia nigra (SN) may render them vulnerable to
neuroinflammatory stimuli. Chronic inhibition of soluble Tumor Necrosis Factor (TNF) with dominant-negative TNF
inhibitors protects DA neurons in rat models of parkinsonism, yet the molecular mechanisms and pathway(s) that
mediate TNF toxicity remain(s) to be clearly identified. Here we investigated the contribution of ceramide
sphingolipid signaling in TNF-dependent toxicity.
Results: Ceramide dose-dependently reduced the viability of DA neuroblastoma cells and primary DA neurons and
pharmacological inhibition of sphingomyelinases (SMases) with three different inhibitors during TNF treatment
afforded significant neuroprotection by attenuating increased endoplasmic reticulum (ER) stress, loss of
mitochondrial membrane potential, caspase-3 activation and decreases in Akt phosphorylation. Using lipidomics
mass spectrometry we confirmed that TNF treatment not only promotes generation of ceramide, but also leads to
accumulation of several atypical deoxy-sphingoid bases (DSBs). Exposure of DA neuroblastoma cells to atypical
DSBs in the micromolar range reduced cell viability and inhibited neurite outgrowth and branching in primary DA
neurons, suggesting that TNF-induced de novo synthesis of atypical DSBs may be a secondary mechanism involved
in mediating its neurotoxicity in DA neurons.
Conclusions: We conclude that TNF/TNFR1-dependent activation of SMases generates ceramide and sphingolipid
species that promote degeneration and caspase-dependent cell death of DA neurons. Ceramide and atypical DSBs
may represent novel drug targets for development of neuroprotective strategies that can delay or attenuate the
progressive loss of nigral DA neurons in patients with PD.
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The exact molecular mechanisms that contribute to
pathogenesis in Parkinson’s disease (PD) have not been
well delineated; many different cellular processes have
been implicated in PD, including diminished function of
the ubiquitin proteasome system, generation of reactive* Correspondence: malu.tansey@emory.edu
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reproduction in any medium, provided the oroxygen species, endoplasmic reticulum (ER) stress, com-
promised mitochondrial function and protein aggrega-
tion (Reviewed by [1]). Additionally, inflammation and
activated microglia have been generally implicated in PD
pathology [2-7] and increased levels of pro-inflammatory
cytokines such as TNF, IL-1β and IL-6, have been
observed in the cerebral spinal fluid (CSF) and striatum
of PD patients relative to healthy age-matched controls
[8]. Furthermore, gene polymorphisms in inflammatory
genes (TNF-308 and IL-1β-511) have been associated
with an increased risk of developing PD [9]. Specifically,
we have previously reported that blocking soluble TNF
(solTNF) signaling with novel dominant-negative TNFl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in vitro and in vivo [10]. Soluble TNF signals through
the canonical transmembrane death receptor TNF re-
ceptor 1 (TNFR1) to potently transduce inflammatory
stimuli [11,12]. TNFR1 is constitutively expressed by
most cell types, including DA neurons, which are acutely
sensitive to TNF-induced toxicity [13-15]. However,
TNFR1 can elicit signaling through numerous down-
stream effectors, including p38, JNK, MAPK, and cera-
mide (Reviewed by [16]) but identification of specific
pathways required for TNF-induced cytotoxicity in DA
neurons has not yet been forthcoming.
The aim of this study was to test the hypothesis that
ceramide signaling cascades are an important effector
arm of TNF-mediated cytotoxicity in DA neurons.
Ceramide is a sphingolipid with a well-established role in
cell membrane homeostasis [17]. However, a wealth of
studies over the past decade established the role of
ceramide and its downstream metabolites as second
messenger sphingolipids due to their rapid and transient
generation in cells and their ability to modulate a variety
of physiologic and stress responses [18-20]. Specifically,
ceramide has been implicated in the cell death pathway
activated by the death domain receptor ligands TNF and
Fas-L [21,22]. Additionally, ceramide has been shown to
activate apoptosis in primary cortical neurons [23] and in
primary neuronal cultures from embryonic mesenceph-
alon [24], but its role as a critical downstream effector of
TNF-induced apoptosis in DA neurons has not been
fully delineated. To explore the role of ceramide signal-
ing in the TNF-dependent cytotoxicity of DA neurons,
we used both primary neuronal cultures from embryonic
rat ventral mesencephalon and the MN9D dopamine
neuron-like cell line [25] which is a hybridoma line
derived from fusion of murine embryonic ventral mesen-
cephalon and neuroblastoma cells and is often used as
an in vitro model of DA neurons [26,27] because the
cells express high levels of tyrosine hydroxylase (TH),
the rate limiting enzyme in dopamine biosynthesis, and
efficiently synthesize, store and release dopamine [28];
additionally, their sensitivity to oxidative stress and in-
flammatory stimuli is similar to that of primary DA
neurons from ventral midbrain [25-27]. Here we report
that TNF and ceramide exert dose-dependent cytotoxic
effects on DA neuroblastoma cells and primary DA neu-
rons. Functionally, inhibitors of SMase activity which block
sphingomyelin hydrolysis and ceramide generation attenu-
ated TNF-induced cytotoxicity, decreases in phospho-Akt,
increases in caspase 3 cleavage as well as mitochon-
drial membrane potential changes, and ER stress in DA
cells. Ultimately, the mechanisms of TNF-induced cyto-
toxicity in DA cells culminated in and were found to
be completely dependent on caspase signaling, suggest-
ing a model in which ceramide/sphingolipid signalingcascades are key effectors of TNF-dependent apoptotic
death in DA neurons. Our data also revealed that TNF
treatment not only activates sphingomyelinases
(SMases) to produce ceramide but also leads to gen-
eration of several other atypical deoxy-sphingoid bases
(DSBs) including desoxymethylsphingosine (1-desoxy-
MeSo), deoxysphinganine (deoxySa), and desoxymethyl-
sphinganine (1-desoxyMeSa); when added exogenously
in vitro, some of these DSBs inhibit neurite outgrowth
and are toxic to DA neurons. These findings suggest that
multiple sphingolipid mediators may be responsible for
mediating TNF neurotoxicity and identification of specific
sphingolipid metabolites may reveal opportunities for
drug development to delay or prevent DA neuron
degeneration.
Experimental procedures
Primary and Cell Line Cultures
The MN9D dopaminergic neuroblastoma cell line was
developed by Dr. Alfred Heller [25] and was a generous
gift from Dr. Michael Zigmond, at the University of
Pittsburgh. MN9D cells were grown in culture in sterile
complete media (CM) which consisted of: high glucose
(4,500 mg/L) Dulbecco’s Modified Eagle Medium
(DMEM, Sigma, D5648) dissolved in sterile tissue cul-
ture tested water (Sigma) supplemented with 10% fetal
bovine serum (FBS, Hyclone Fetal Clone III), sodium bi-
carbonate (3.7 g/L, Sigma), 25 mM HEPES (Sigma), and
1% Penicillin/Streptomycin (Sigma) at a final pH of 7.3
in a humidified 5% CO2 incubator at 37°C. MN9D cell
cultures were seeded in 75 cm2 tissue culture flasks
(Costar) and plated at a density of 7,500 cells per well
for 96-well plates (100 μL CM per well); 35,000 cells per
well (500 μL CM per well) for 24-well plates; and 50,000
cells per well (2 mL CM per well) for 6-well plates. After
plating and allowing attachment of cells overnight in
CM, MN9D cells were differentiated for 72 hrs via a
complete media change to differentiation media (DM)
which contained serum free DMEM (same CM as above,
except FBS was excluded) supplemented with 5 mM 2-
Propylpentanoic acid (valproic acid, Sigma, P6273) and
1X N2 supplement (Invitrogen) as described in previous
protocols [26].
Primary mixed neuron-glia cultures from rat ventral
mesencephalon (rat MES) were prepared as described
previously [10]. Briefly, ventral mesencephalic tissues
were dissected from embryonic day 14 (E14) Fischer 344
rats and dissociated with mild mechanical trituration.
Cells were plated into 96-well culture plates pre-coated
with poly-D-lysine (0.1 mg/mL) and laminin (20 g/mL)
at a density of 2.5 x105 cells/mL in DMEM/F12 supple-
mented with 10% FBS, 1 g/L glucose, 2 mM L-glutam-
ine, 1 mM sodium pyruvate, 100 M non-essential amino
acids, 50 U/mL penicillin, 50 g/mL streptomycin, and
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tures were maintained at 37°C in a humidified atmos-
phere of 5% CO2/95% air. Cultures were replenished
2 days later with 100 μL/well fresh medium lacking
bFGF and were treated 5 days after plating. For treat-
ment, the cultures were maintained in 100μL/well of
medium supplemented with 2.5% FBS and lacking bFGF.
MTS Metabolic Assays
Treated diff-MN9D cells in 96-well plates were evalu-
ated for overall viability using the MTS assay (Promega,
CellTiter 96 AQueous One Solution Cell Proliferation
Assay) according to the manufacturer’s instructions.
Twenty microliters (20 μL) of the MTS reagent was
added to cell cultures with DM-containing treatments
and/or inhibitors. The cells were incubated with the
MTS reagent at 37°C, 5% CO2 for 2 hrs prior to colori-
metric quantification of MTS reduction into a blue for-
mazan by-product by metabolically active cells. The
absorbance of blue formazan was measured at 492 nm
wavelength using a Multiskan Ascent absorbance plate
reader (Thermo Labsystems).
LDH Release Cytotoxicity Assay
Treated diff-MN9D cells in 96-well plates were evaluated
for cytotoxicity using an LDH release assay (Clontech
Laboratories, Mountain View, CA) as per the manu-
facturer’s instructions. LDH reactions were measured
at a wavelength of 492 nm on an absorbance plate reader
(Thermo Lab Systems Multiskan Ascent). The maximum
LDH activity was determined by lysing the cells with 1%
Triton X-100.
Neurite Length and Branching Studies
After treatment with the specified sphingolipids, primary
rat mesencephalic (MES) cultures were fixed with 4%
paraformaldehyde, stained with anti-MAP2 (1:1000,
Millipore, MAB3418) and anti-TH antibodies (1:1000,
Millipore, AB152) and counterstained by DAPI. Images
were captured on an IMAGEXPRESS 5000A automated
cellular imaging and analysis system. When analyzing
the morphology of TH-positive neurons, the neurite out-
growth application module of MetaXpress software was
used and multi-parameter analysis measurements were
performed.
Sphingomyelinase and Ceramide Synthesis Inhibition
Diff-MN9D cells in 96-well plates were pre-treated in
triplicate or quadruplicate with one of four different
pharmacological inhibitors: the acid sphingomyelinase
(ASMase) inhibitor desipramine HCl, used at 1 μM and
5 μM, (Sigma, D3900, dissolved in sterile H2O), the neu-
tral sphingomyelinase (NSMase) inhibitor GW4869,
used at 10 μM, and 20 μM, (Calbiochem, No. 567715,dissolved in DMSO, aliquotted and stored under argon
gas), the synthetic bisphosphonate sSMase inhibitor 7c,
also known as ARC39, used at 1 μM, (a generous gift
from Dr. Christoph Arenz, Humboldt University in
Berlin, Germany), the serine palmitoyltransferase inhibi-
tor myriocin (a generous gift from Dr. Philip Scherer,
UT Southwestern Medical Center at Dallas), dissolved in
ethanol and used at 10 μM or the ceramide synthase in-
hibitor Fumonisin B1, used at 50 μM (Axorra LLC, No.:
350-017-M001, dissolved in sterile H2O). Diff-MN9D
cells were pre-treated with ceramide inhibitors or con-
trol diluents for 30 minutes via a 50% media change with
DM that contained a 2X concentration of the respective
inhibitor or control diluent (i.e. 50 μL of the initial
100 μL DM was removed and replaced with 50 μL of
DM containing a 2X concentration of a ceramide inhibi-
tor for a final volume of 100 μL with 1X inhibitor). After
pre-treatment with ceramide inhibitors for 30 minutes,
TNF was added by a 1:100 dilution of a TNF stock con-
centration into media that contained ceramide inhibitors
(1 μL of 100X TNF was added to 100 μl DM). In the
case of GW4869, which declines in effective NSMase-
inhibition over time [29] the GW4869 reagent was
added to DM 30 minutes prior to TNF treatment by a
50% media change and was then re-added 24 hrs after
initial GW4869 pre-treatment by addition of a 1:100 di-
lution of a GW4869 stock concentration (1 μL of 100X
GW+100 μL DM to equal 1X) into DM already con-
taining TNF treatments. Diff-MN9D cells were incu-
bated at 37°C, 5% CO2 for 48 hrs post TNF treatment
prior to determination of cell viability by MTS assay.
Western blots for ER stress, caspase-3, and p-AKT activation
MN9D cells were plated on 6-well plates at the density
of 50,000 cells/well. Twenty-four to forty-eight hours
later, the complete media was changed into differenti-
ation media and the cells were neurally differentiated
for 72 hours. Before TNF treatment, diff-MN9D cells
were pre-incubated with desipramine or GW4869 for
1 hour. After 24- hours treatment with ceramide, TNF,
TNF/Des or GW, cell lysates were collected in 200 uL
SDS-PAGE loading buffer. When running SDS-PAGE,
15ul of sample lysate was loaded in each well. GAPDH
and α-Tubulin were used as controls for densitometry
quantification. The quantified data shown represent at
least three independent experiments.
Cytofluorometric Analysis of Mitochondrial Membrane
Potential
Mitochondrial membrane potential in diff-MN9D cells
was measured as previously described [30]. Briefly,
MN9D cells were seeded into black-walled, clear-
bottomed 24-well plates onto Poly-L-Lysine (PLL)
coated (Sigma, P2636, MW=30,000-70,000, 1 mg/mL)
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Carolina Biological Supply) at a density of 35,000 cells
per well in 500 μL CM. The MN9D cells were incubated
overnight at 37°C, 5% CO2 and were then differentiated
via a complete media change with DM. After 72 hrs in
DM, the diff-MN9D cell cultures were treated with C2-
Cer or DMSO vehicle, or TNF or media vehicle via a
complete media change with 1X treatment in DM. After
incubation with C2-Cer for 18 hrs or TNF for 36 hrs,
tetra methyl rhodamine methyl ester (TMRM) (Invitrogen,
T668, re-suspended in DMSO) was loaded into treated
diff-MN9D cells at 150 nM in warm assay buffer
(AB, 500 μL per well) which consisted of: NaCl
(80 mM), KCl (75 mM), D-glucose (25 mM) and HEPES
(25 mM) diluted in sterile H2O and adjusted to a final
pH of 7.4. To control for TMRM background cytofluor-
escence, carbonyl cyanide 3-chlorophenylhydrazone
(CCCP, Sigma, C2759) was used. At the time of incuba-
tion with TMRM, 10 μM CCCP (re-suspended in
DMSO) was co-added with TMRM in AB to parallel
wells of diff-MN9D cells treated with TNF or C2-Cer.
TMRM and TMRM/CCCP loaded cells were incubated
for 15 minutes in a humidified incubator with 5% CO2
at 37°C prior to quantification of TMRM cytofluores-
cence by excitation at 544 nm wavelength and emission
at 590 nm wavelength on a FLUOstar Omega plate
reader (BMG Scientific). The TMRM signal in TMRM/
CCCP conditions is considered background, and this
signal was used to normalize TMRM cytofluorescence
values for each respective TNF or C2-Cer condition.
Caspase Inhibition and BAPTA-AM Studies
Diff-MN9D cells in 96-well plates were treated in tripli-
cate or quadruplicate with TNF or C2-Cer alone or were
co-treated with one of two caspase inhibitors, 25 μM Z-
VAD-FMK (Z-VAD, a pan caspase inhibitor, obtained
from Promega), or 25 μM Z-IETD-FMK (Z-IETD, a cas-
pase 8-specific inhibitor, obtained from R&D Systems).
The treated diff-MN9D cells were incubated at 37°C, 5%
CO2 with C2-Cer for 24 hrs or with TNF for 48 hrs prior
to determination of overall cell viability via the MTS
assay as described above. For BAPTA-AM studies, diff-
MN9D cells were pre-loaded with the cell permeant
intracellular Ca2+ chelator BAPTA-AM (BAPTA, 10 μM)
30 min prior to treatment with concentrations of C2-Cer.
At the endpoint of the study, cell viability was assayed by
MTS reduction.
Lipidomics for Quantitative Analysis of Complex
Sphingolipids and Sphingoid Base
To perform quantitative analysis of complex sphingoli-
pids and sphingoid bases in MN9D ventral mesenceph-
alon DA neuroblastoma cells in response to TNF
(10 ng/mL) treatment, we employed a lipidomicsapproach based on previously published protocols [31].
For internal standards, the Ceramide/Sphingoid Internal
Standard Mixture II (LM-6005) from Avanti Polar Lipids
(Alabaster, AL, USA) was used with 25 pmol of each of
the following: Sphingosine (C17 base), Sphinganine (C17
base), Sphingosine-1-P (C17 base), Sphinganine-1-P
(C17 base), Lactosyl(ß) C12 Ceramide, C12-Sphingomyelin,
Glucosyl(ß) C12-Ceramide, C12-Ceramide, and C12-
Ceramide-1-P (LM-6005).
Cell Treatments with TNF, Ceramide and Sphingoid Bases
After incubation in DM for 72 hours, diff-MN9D cells cul-
tured in 96-well plates were treated in triplicate or quadru-
plicate by a 50% media change with DM that contained 2X
TNF (recombinant mouse, R&D MT-410), C2-Ceramide
(C2-Cer, N-acetyl-D-Sphingosine, Sigma A7191) or C2-
dihydroceramide (C2-DH-Cer, Sigma, C7980) as a nega-
tive control for C2-Ceramide because it lacks the 4–5
trans bond in the sphingosine moiety and cannot activate
downstream ceramide signaling [22,32]. The TNF was dis-
solved in sterile Phosphate Buffered Saline (PBS, Sigma)
and C2-Cer and C2-DH-Cer were dissolved in DMSO
(Sigma) and aliquotted and stored under argon gas. As a
control in parallel treatments, a DMSO vehicle condi-
tion equivalent to the amount of DMSO in the highest
concentration of C2-Cer/C2-DH-Cer was used. TNF,
C2-Cer or C2-DH-Cer-treated diff-MN9D cells were
incubated at 37°C, 5% CO2 for 72 or 48 hrs respectively,
prior to being evaluated for overall viability using the
MTS assay (described below). TNF, C2-Cer or C2-DH-
Cer treatments of diff-MN9D cells in 24-well or 6-well
plates were done in duplicate or triplicate by a
complete media change from DM to DM containing 1X
TNF, C2-Cer or C2-DH-Cer. Etanercept, an Fc-fusion
protein consisting of TNFR2 and the Fc component of
human immunoglobulin IgG1, was used as a positive
control because it binds TNF and blocks its bioactivity
[10,33].
Lipid-BSA stock solutions of the following sphingoli-
pids from Avanti Polar Lipids were prepared as
per published protocols [34,35]. 1-deoxysphinganine
C18H39NO (Catalog # 860493), 1-desoxymethylsphinganine
C17H37NO (Catalog # 860473); 1-deoxysphingosine
C18H37NO (Catalog# 860470); 1-desoxymethylsphingosine
C17H35NO (Catalog # 860477); C16 ceramide
C34H67NO3 (Catalog # 860516); Sphingosine (d18:1)
C18H37NO2 (Catalog # 860490) and Sphinganine
(d18:0) C18H39NO2 (Catalog # 860498). Briefly, lipids
were placed in Pyrex 13x100 mm borosilicate, screw-
capped glass test tubes with Teflon caps and solubilized
in a volume of ethanol to get a final concentration of
100 mM; sonication and warm tap water were employed
to ensure homogenous resuspension. To make 1:1 (con-
centration) sphingoid base-BSA complex, 20 uL of a
AB














































Figure 1 TNF and ceramide (but not dihydro-Ceramide) reduce
viability of neurally differentiated MN9D dopaminergic (DA)
cells. A, Dose-dependent cytotoxic cell death in diff-MN9D cells
treated with TNF for 72 hrs. All values represent group means
+/− SEM, n = 3–4. One-way ANOVA with Tukey’s post-hoc; * denotes
p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 compared to
vehicle (DMSO, 1%); for comparison between doses # denotes
p < 0.05, n.s. denotes not significant. B, Dose-dependent
C2-Ceramide-induced cytotoxic death in diff-MN9D cells. Cells were
treated with ceramide (C2-Cer), or with equal concentrations of
C2-dihydroceramide (C2-DH-Cer) as a negative control. All values
represent group means +/− SEM, n = 3–4. Two-way ANOVA with
Tukey’s post-hoc test for comparing C2-Cer conditions to C2-DH-Cer
conditions where **denotes p < 0.01, *** denotes p < 0.001. One-way
ANOVA to test for dose-dependent cell death in C2-Cer conditions
where # denotes p < 0.05, ### denotes p < 0.001 relative to vehicle
or different C2-Cer conditions as indicated.
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injected into a 1 mL volume of a BSA (2 mM) solution by
using a Hamilton syringe. To ensure optimal complexing
of the lipids to BSA, tubes were shaken vigorously and
sonicated as needed. When treating the diff-MN9D cells,
different concentrations of sphingoid base-BSA complexs
were prepared in differentiation media and added to diff-
MN9D cells and incubated for 24 hours at the concentra-
tions indicated under “Results”. When treating the rat
MES cultures, sphingoid base-BSA complexes were pre-
pared in treatment media (DMEM/Ham F-12 with 1%
Pen/strep, 1% Glutamine, 1% non-essential amino acids
and 2.5% FBS) without bFGF.
Statistical Analyses
Statistical analyses were performed using GraphPad
Prism5 software (GraphPad Prism, San Diego, CA).
Intergroup differences among the means between the
various dependent variables were analyzed using
one-way ANOVA; when ANOVA indicated significant
differences, it was followed by Tukey’s post-hoc group
comparison test. Differences among group means be-
tween two independent variables were analyzed by two-
way ANOVA, followed by Tukey’s post-hoc test when
the ANOVA indicated significant differences. Values
expressed are the group means +/- standard error of the
mean (SEM).
Results
TNF and ceramide induce cytotoxicity in differentiated
MN9D cells and in primary DA neurons from ventral
mesencephalon
In light of our previous findings showing that ventral
mesencephalon dopaminergic (DA) neurons are acutely
sensitive to TNF in vitro and in vivo [10], we hypothe-
sized that ceramide sphingolipids are critical effectors
of TNF-induced cytotoxicity. First, we aimed to estab-
lish a correlation between TNF-dependent ceramide
generation and the effect of TNF or ceramide exposure
on the viability of neuronally differentiated MN9D cells
or primary DA neurons. We found that TNF dose-
dependently decreased the viability of diff-MN9D cells
as measured by the MTS metabolic assay (Figure 1A).
To test the hypothesis that elevated ceramide is directly
toxic to diff-MN9D cells, we treated the cells with vari-
ous concentrations of C2-Cer or C2-dihydroceramide
(C2-DH-Cer) as a negative control; C2-DH-Cer is an
analog of C2-Cer lacking the 4–5 trans bond in the
sphingosine moiety that is incapable of activating
downstream ceramide signaling [22,32]. We found that
C2-Cer but not C2-DH-Cer induced dose-dependent
decreases in diff-MN9D viability (Figure 1B). We previ-
ously determined that non-differentiated MN9D (non-
diffMN9D) cells are not sensitive to concentrations ofTNF that elicit cytotoxicity in diff-MN9D cells [26].
Similarly, C2-Cer was not cytotoxic to non-diff-MN9D
cells (Additional file 1: Figure S1).
TNF-induced neurotoxicity in DA cells and neurons is
attenuated by SMase inhibitors
Ceramide can be generated either through a de novo
biosynthesis pathway involving several enzymatic reac-
tions downstream of the initial condensation of serine
and palmitoyl-CoA on the cytoplasmic surface of the ER

































































































Figure 2 TNF-induced neurotoxicity in DA cells and neurons is
attenuated by SMase inhibitors. A, TNF-induced cytotoxic cell
death is dependent on SMase hydrolysis of sphingomyelin. Diff-
MN9D cells were pre-treated for 30 minutes with 5 μM desipramine
(Des) or 10 μM GW4869 or 1 μM ARC39 followed by 5 ng/mL TNF
for 48 hrs prior to MTS viability assay. Cell viability was measured by
the MTS assay described under Methods. All values represent group
means +/− SEM, n =3 - 4. One-way ANOVA with Tukey’s post-hoc; #
denotes difference between TNF and vehicle at p < 0.001, * and ***
denote difference from TNF alone at p < 0.05 or p < 0.001,
respectively. B, TNF induced dose-dependent death of primary
ventral mesencephalon DA neurons with SMase inhibitors affording
robust rescue; 5 μM Desipramine (Des); 10 μM GW4869. All values
represent group means +/− SEM, n =3 - 4. One-way ANOVA, Tukey’s
post-hoc test to compare the extent of dose-dependent cell death
in response to increasing concentrations of TNF and two-way
ANOVA with Tukey’s post-hoc test to compare inhibitor conditions
to 10 ng/mL TNF without inhibitors. * denotes p < 0.05, ** denotes
p < 0.01, *** denotes p < 0.001.
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hydrolyze sphingomyelin (SM) to ceramide [36]. We
hypothesized that activation of SMases at the plasma
membrane by the activated TNFR1/TNF receptor com-
plex is the mechanism by which TNF exposure leads to
ceramide signaling and cytotoxicity in DA cells. To test
this hypothesis directly, we pre-treated diff-MN9D cells
with different inhibitors of SMases for 30 minutes fol-
lowed by treatment with TNF for 48 hrs. We pre-treated
diff-MN9D cells with three different compounds that in-
hibit SMases with different mechanisms of action. Pre-
incubation with desipramine (Des) (an inhibitor of acid
sphingomyelinase, ASMase[37]), GW4869 (an inhibitor
of neutral sphingomylinase, NSMase [38]), or with 7c,
also known as ARC39 (an inhibitor of lysosomal and
secreted ASMase [39]) at the concentrations indicated
all significantly attenuated TNF-induced cytotoxicity of
diff-MN9D cells as measured by the MTS assay
(Figure 2A). To confirm and extend these findings, we
assayed the extent to which two of these SMase inhibi-
tors attenuated TNF-induced death of DA neurons in
primary neuron-glia cultures from rat ventral mesen-
cephalon. Consistent with the results in MN9D cells,
Des and GW4869 protected primary DA neurons from
TNF-induced death (Figure 2B) to an extent comparable
to that achieved in previous studies using the soluble
TNF-selective inhibitor XENP345 [10]. Together these
pharmacological data strongly suggest that TNF-
dependent activation of SMases results in SM hydrolysis
and generation of ceramide that is cytotoxic to DA neu-
rons, compromising their viability. To confirm that the
ceramide-generating pathway involved in mediating
TNF-dependent cytotoxicity is due to SM hydrolysis by
SMases rather than through de novo ceramide forma-
tion, we repeated these experiments using pharmaco-
logical inhibitors of the de novo ceramide biosynthesis
pathway. We observed that inhibition of the enzyme
serine palmitoyltransferase (the rate-limiting enzyme in
de novo ceramide biosynthesis) by myriocin or inhibition
of the enzyme ceramide synthase (which converts sphin-
ganine to dihydroceramide) by Fumonisin B1 did not
mitigate TNF-induced cytotoxicity in diff-MN9D cells
(Additional file 2: Figure S2). Collectively, our data sup-
port a model in which SMase hydrolysis of SM to form
ceramide is requisite for TNF-induced cytotoxicity in
diff-MN9D cells and DA neurons.
TNF and C2-Ceramide-induced cytotoxicity involves
endoplasmic reticulum stress pathways
TNF and ceramide have been shown to impinge on ER
stress mechanisms in non-neuronal cells types [40,41] and
ER stress has been implicated as a potentially important
pathway in PD pathogenesis [42], being coupled to the cell
death program in DA cells in response to the toxinparaquat [43]. Therefore, we investigated the extent to
which activation of ER stress pathways by TNF are
dependent on ceramide generation by SMase activity in
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TNF treatment of diff-MN9D cells increased protein
expression of key ER stress transducers, including activat-
ing transcription factor 6 (ATF6), ER- resident PKR-like
eIF2α kinase (PERK), and inositol requiring enzyme-1
(IRE). We found that the increased expression of ER stress
proteins by TNF and C2-Cer was comparable to increased
protein levels caused by the positive control tunicamycin,
(Figure 3) which is known to potently induce ER stress by
inhibiting protein N-glycosylation [44]. These results sup-
port a model in which TNF employs ceramide signaling to
elicit ER stress in DA cells.TNF-induced decrease in mitochondrial membrane potential
and LDH release in DA cells is ameliorated by SMase
inhibitors
TNF has been reported to cause rapid decreases in mito-
chondrial membrane potential and coincident increases in
reactive oxygen species [45]. Consistent with our hypoth-
esis that ceramide is an important downstream effector of
TNF cytotoxicity, ceramide itself has been shown to dir-
ectly affect the mitochondrial electron transport chain
[46]. To further elucidate the mechanisms of TNF and
C2-Cer-induced cytotoxicity and to determine if TNF/
ceramide signaling in diff-MN9D cells impinges on mito-
chondria, we investigated whether TNF or C2-Cer ad-
versely impact mitochondrial membrane potential by
evaluating tetramethyl rhodamine methyl ester (TMRM)
cytofluorescence. TMRM is a cationic mitochondrial-
selective probe that accumulates in the negatively charged
mitochondrial membrane in proportion to mitochondrial
membrane potential. Diff-MN9D cells treated with 5 ng/
mL TNF for 36 hrs or 5 or 10 μM C2-Cer for 18 hrs
exhibited compromised mitochondrial membrane poten-
tial as evidence by reduced TMRM cytofluorescence rela-
tive to vehicle treated diff-MN9D cells (Figure 4A),
lending support to the interpretation that both TNF and
C2-Cer adversely affect mitochondrial integrity in diff-
MN9D cells. Moreover, the SMase inhibitors desipra-
mine and GW4869 partially restored the TMRM signal
in diff-MN9D cells (Figure 4A). To confirm and extend
these findings we performed an additional assay to
measure TNF-induced cytotoxicity. Diff-MN9D cells
were treated for 18 hrs with 5 or 10 μM C2-Cer or 5 ng/
mL TNF; lactate dehydrogenate (LDH) release was then
measured. In agreement with results from MTS assays,
pre-treatment with SMase inhibitors (Desipramine or
GW4869) attenuated TNF-induced LDH release. The
TNF inhibitor etanercept was used as a positive control.
These data support a model in which TNF-induced
cytotoxicity is mediated via ceramide-dependent signal-
ing leading to disruption of mitochondrial membrane
potential in DA cells.Inhibition of SMases during TNF exposure attenuates
caspase 3 cleavage in DA cells
Loss of mitochondrial membrane potential and release
of cytochrome C from mitochondria generally precede
caspase-dependent apoptotic cell death and a wealth of
data has linked TNF bioactivity to caspase activation
and apoptosis in various cell types (reviewed in [47]).
Similarly, ceramide has been reported to cause apoptotic
cell death by altering the Bax/Bcl2 ratio which triggers
cytochrome C release from the mitochondria and results
in activation of the caspase-9/-3 cascade in C6 glioma
cells [48]. Therefore, we investigated the extent to which
addition of SMase inhibitors during TNF treatment atte-
nuated caspase signaling. Western blot analyses showed
that desipramine and GW4869 significantly attenuated
caspase 3 cleavage in TNF-treated diff-MN9D cells
(Figure 5A, B). To correlate this finding with TNF-
induced cytotoxicity in diff-MN9D cells, we determined
the extent to which pan-caspase inhibition (with
Z-VAD) or caspase 8 inhibition (with Z-IETD) could
ameliorate TNF dose-dependent loss of viability in diff-
MN9D. We found that both caspase inhibitors robustly
protected diff-MN9D cells from TNF-induced cytotox-
icity at all TNF concentrations (Figure 5C), demon-
strating that caspase activation is obligate for TNF-
induced apoptotic cell death in terminally differentiated
MN9D cells and suggesting that TNF-dependent cera-
mide generation promotes activation of caspase 8 and
caspase 3 signaling cascades that lead to apoptotic
death in DA cells and neurons. Interestingly, we also
found that C2-Cer-induced cytotoxic cell death in diff-
MN9D cells was not significantly blocked by Z-VAD or
Z-IETD (Figure 6A), which is not entirely surprising
since exogenously added C2-Cer would act down-
stream of TNF/TNFR1-dependent caspase 8 activation.
However, we hypothesized that TNF-stimulated cera-
mide exerts cytotoxicity in DA cells by dysregulating
intracellular Ca2+ based on reports that implicate de-
fective Ca2+ homeostasis in apoptotic cell death of
neuronal populations induced by aberrant sphingolipid
metabolism [49]. To test this hypothesis directly, we
pre-incubated diffMN9D cells with BAPTA-AM prior
to exposure to C2-Cer and found that buffering intra-
cellular free calcium nearly ablates C2-Cer-induced
toxicity in diff-MN9D cells (Figure 6B), suggesting that
elevation of [Ca2+]i contributes to C2-Cer-induced
neurotoxicity.
TNF and Ceramide attenuate p-Akt activation to facilitate
TNF-induced neurotoxicity in DA cells
Next, we tested the hypothesis that TNF-dependent cer-
amide-induced cytotoxicity in diff-MN9D cells may also
result from reduced activation of pro-survival pathways,
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Figure 3 (See legend on next page.)
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Figure 3 TNF-induced ER stress responses in MN9D dopaminergic (DA) cells were attenuated by SMase inhibitors. A, Diff-MN9D cells
were pre-treated with 5 μM Desipramine (Des) or 10 μM GW4869 followed by treatment with 5 ng/mL TNF for 24 hours. Cell lysates were
harvested for SDS-PAGE and were analyzed by immunoblot using antibodies against the ER stress proteins ATF6, IRE1, and PERK or GAPDH for
normalization. Dihydro-ceramide (DH-C2-Cer at 10 μM) and tunicamycin (Tunicam. at 0.1 μg/mL) were used as negative and positive controls,
respectively. B, Quantification of western blots in A. All values represent group means +/− SEM, n = 3–4. One-way ANOVA with Tukey’s post-hoc









































































































Figure 4 TNF- induced decreases in mitochondrial membrane
potential were attenuated by SMase inhibitors. A, Treatment of
diff-MN9D cells for 18 hrs with 5 or 10 μM C2-Cer or 5 ng/mL TNF
comprised mitochondrial membrane potential. TMRM
cytofluorescence was normalized to CCCP+ Veh or CCCP+ TNF, as
CCCP uncouples mitochondrial membranes. Pre-treatment with the
SMase inhibitors Desipramine or GW4869 attenuated the
TNF-induced decreases in mitochondrial membrane potential. All
values represent group means +/− SEM, n = 3–4. One-way ANOVA
with Tukey’s post test; * denotes p < 0.05, *** denotes p < 0.001
compared to ‘Veh’; # denotes p < 0.05 compared to TNF alone. B,
Treatment of diff-MN9D cells for 18 hrs with 5 or 10 μM C2-Cer or
5 ng/mL TNF induced cytotoxicity as measured by LDH release.
Pre-treatment with SMase inhibitors (Desipramine or GW4869)
attenuated TNF-induced cytotoxicity; the TNF inhibitor (etanercept)
was used as a positive control. All values represent group means
+/− SEM, n = 3–4. One-way ANOVA with Tukey’s post test;
### denotes p < 0.001 compared to vehicle; *** denotes p < 0.001
compared to TNF alone.
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pro-survival signaling in the majority of neurons [50,51]
We found that TNF treatment reduced p-Akt levels in
DA cells and SMase inhibitors robustly blocked this
effect (Figure 7). Together with results from caspase
inhibition experiments, these data suggest that TNF
treatment leads to generation and accumulation of
ceramide (and perhaps other downstream sphingolipid
metabolites), leading to cytotoxicity in DA neurons via
increased ER stress, compromised mitochondrial
membrane potential, increased caspase-3 dependent
apoptotic signaling cascades, and attenuation of
phospho-Akt-dependent pro-survival signaling.TNF induces generation of ceramide and atypical
sphingoid bases in dopaminergic neuroblastoma cells
Given that SMase inhibition affords significant protection
from TNF-dependent toxicity in DA neuroblastoma cells
and primary DA neurons, it was of interest to confirm that
TNF treatment results in detectable formation of cera-
mide in vivo. We used a lipidomics approach to enable
quantitative analysis of complex sphingolipids and sphin-
goid bases in lipid extracts of MN9D cells exposed to PBS
or soluble TNF for up to 48 hours. We chose to use DA
neuroblastoma cells for our analysis because a homoge-
neous population of cells is needed for a meaningful result
and primary DA neurons only make up a small percentage
of total neurons in ventral midbrain cultures. Our analyses
indicated that TNF exposure significantly increased the
intracellular levels of total ceramide (Cer), sphingomyelin
(SM), and hexosylceramide (HexCer) (Figure 8A) as well
as several sphingoid bases including sphingosine (So),
sphinganine (Sa), sphingosine-1-P (SoP), sphinganine-1-P
(SaP), and the atypical sphingoid bases deoxy-sphinganine
(deoxySa or DEOSA) and desoxymethylsphinganine
(desoxyMeSa or DEOMSA) (Figure 8B). TNF-induced
increases in the levels of other complex sphingolipids in-
cluding deoxydihydro-Ceramide (deoxyDH-Cer) and
deoxyceramide (deoxyCer) were not consistently or repro-
ducibly detected (data not shown). These data raise the
possibility that in addition to ceramide, any of these
additional sphingolipids could be critical second messen-
gers involved in mediating TNF cytotoxicity in DA neuro-
blastoma cells.
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differentiated MN9D cells and inhibit neurite outgrowth in
primary DA neurons from ventral mesencephalon
Based on results from lipidomics analyses (Figure 8B)
which indicated that TNF exposure not only increased
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Figure 5 (See legend on next page.)in the intracellular levels of several atypical deoxy-
sphingoid bases (DSBs), including deoxysphinganine
(deoxySa or DEOSA) and desoxymethylsphinganine
(desoxyMeSa or DEOMSA), we wanted to test these
atypical DSBs for direct cytotoxic effects on cells. These
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(See figure on previous page.)
Figure 5 TNF- and ceramide-induced caspase-3 cleavage was attenuated by SMase inhibitors and caspase inhibitors rescued
differentiated MN9D cells from TNF-induced cytotoxicity. A, Diff-MN9D cells were treated for 3 days with 5 ng/mL TNF in the presence or
absence of the ASMase inhibitor Desipramine (Des, 5 μM) or the NSMase inhibitor GW4869 (10 μM) and were thereafter harvested for SDS-PAGE
and immunoblot analysis of total caspase 3 or cleaved caspase 3. B, Quantification of western blot analysis of caspase 3 and cleaved caspase 3.
One-Way ANOVA with Tukey’s post-hoc test to compare inhibitor conditions to TNF alone, where ** denotes p < 0.01, ***denotes p < 0.001. C,
MTS assay for cell viability in diff-MN9D cells. TNF induced dose-dependent death of diff-MN9D cells and was caspase-dependent. Co-treatment
with TNF plus the pan-caspase inhibitor Z-VAD (25 μM) or with TNF plus the caspase-8-specific inhibitor Z-IETD (25 μM) robustly blocked
TNF-induced cell death in diff-MN9D cells. All values represent group means +/− SEM, n = 3–4. One-way ANOVA with Tukey’s post-hoc test to
compare the effect of specified TNF concentrations on diff-MN9D viability without caspase inhibitors in the MTS assay, where # denotes p < 0.05,
## denotes p < 0.01, and ### denotes p < 0.001 compared to ‘Veh’ or between two concentrations. Two-way ANOVA with Tukey’s post-hoc to
compare effects of caspase inhibitors at each TNF concentration where *** denotes p < 0.001 compared to no caspase inhibitor.
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complex sphingolipids nor degraded by the regular
sphingolipid catabolism, raising the possibility that
they may accumulate within DA neurons and may
be cytotoxic. Therefore, we tested the extent to which
1-deoxySa, 1-desoxyMeSa, and 1-desoxyMeSo induce
dose-dependent cytotoxicity in diff-MN9D cells and
found that all three induced dose-dependent cytotoxicity
with an IC50 around 15 μM (Figure 9). To confirm and
extend the significance of these findings, we investigated
the cytotoxicity of these atypical sphingoid bases on pri-
mary cultures from rat ventral mesencephalon. We
found that only 1-deoxySa significantly reduced the
number of neuritic branches and outgrowths per DA
neuron at concentrations as low as 0.5 μM (Figure 10); a
trend towards compromising DA neuron viability was
also evident but it did not reach statistical significance.
No significant cytotoxic effects on primary DA neurons
by 1-desoxyMeSa and 1-desoxyMeSo were observed
(Additional file 3: Figure S3).
Discussion
The purpose of these studies was to test the hypothesis
that ceramide-dependent signaling mediates TNF-
induced cytotoxicity and degeneration of DA neurons.
Our results indicate that exposure of neurally differen-
tiated DA neuroblastoma cells to soluble TNF induced
activation of membrane-bound sphingomyelinases
(SMases) and sphingomyelin (SM) turnover resulting in
generation of ceramide as measured by lipidomics mass
spectrometry. Direct addition of C2-ceramide to DA
neuroblastoma cells or primary DA neurons in vitro
resulted in dose-dependent cytotoxicity, and pharmaco-
logical inhibition of SMases with three different inhibi-
tors of SMase function to block ceramide generation
during TNF exposure (but not inhibitors of de novo
ceramide synthesis) afforded significant protection from
TNF-induced cytotoxicity. Although desipramine can
exert SMase-independent effects on cells [52], two other
inhibitors with greater specificity for SMase (GW4869
and ARC39) afforded similar protection against TNF-induced cytotoxicity. Based on these findings, we
propose a model by which binding of soluble TNF to
TNFR1 on the cell surface of DA neurons activates
SMases to generate ceramide and trigger downstream
signaling cascades that compromise survival of DA
neurons by eliciting ER stress, reducing mitochondria
membrane potential, leading to activation of caspase-3-
dependent pro-apoptotic signaling and inhibition of Akt-
dependent pro-survival signaling cascades which com-
bine to compromise survival of DA neurons (Figure 11).
Interestingly, TNF treatment also induced SM biosyn-
thesis (Figure 8A); the significance of this novel finding
is unknown, but TNF and lipopolysaccharide (LPS) have
both been reported to induce sphingolipid biosynthesis
in liver [53] and macrophages [54]. It is also worth
noting that increases in atypical deoxy-sphingoid bases
(DSBs) were detectable in DA cells after prolonged
exposure to TNF (Figure 8B), the potential significance
of which is discussed below.
Glycosphingolipid (GSL) metabolism represents a
metabolic cross point that interconnects lipid (acyl-CoA)
and amino acid (serine and alanine) metabolism. For a
detailed review of the metabolic interrelationships that
account for the tens of thousands of molecular subspecies
in the mammalian sphingolipidome, the reader is referred
elsewhere [55,56]. Briefly, ceramide (Cer) consists of a
fatty acid acyl chain that varies in length and saturation,
and a sphingoid base that differs in the number and
position of double bonds and hydroxyl groups. Tissue-
and cell type-specific ceramide synthases control the
length of the fatty acid chain of ceramide. Sphingoid bases
are formed from the precursors L-serine and palmitoyl-
CoA in a reaction catalyzed by serine-palmitoyltransferase
(SPT). SPT metabolizes other acyl-CoAs besides palmitoyl-
CoA but also shows variability towards the use of other
amino acid substrates. For instance, SPT is also able to
metabolize alanine, which results in the formation of an
atypical deoxy-sphingoid base (DSB). These atypical and
relatively novel DSBs are devoid of the C1-hydroxyl group
of sphingosine (SA) and are therefore neither metabolized































































Figure 6 Disruption of calcium homeostasis (but not caspase
signaling) is a primary mechanism by which C2-Ceramide
induces cytotoxicity in dopaminergic MN9D cells. A, The MTS
assay for cell viability in diff-MN9D cells. Co-treatment with the
pan-caspase inhibitor Z-VAD (25 μM) or the caspase-8-specific
inhibitor Z-IETD (25 μM) attenuated cytotoxicity in diff-MN9D cells
induced by C2-Cer concentrations at and below 5 μM but not
above 5 μM. All values represent group means +/− SEM, n = 3–4.
One-way ANOVA with Tukey’s post-hoc test to compare the effect
of specified C2-Cer concentrations on diff-MN9D viability to vehicle
without caspase inhibitors in the MTS assay, where ### denotes
p < 0.001 compared to vehicle or between two C2-Cer
concentrations. Two-way ANOVA with Tukey’s post-hoc to compare
effects of caspase inhibitors at each C2-Cer concentration where
* denotes p < 0.05 and *** denotes p < 0.001 compared to no
caspase inhibitor. B, Pre-loading of diff-MN9D cells with cell permeant
BAPTA-AM (10 μM) to buffer intracellular Ca2+ transients significantly
attenuated cytotoxicity induced by C2-Cer. Cell viability was assayed
by MTS reduction. One-way ANOVA with Tukey’s post-hoc test;































































Figure 7 TNF-induced decreases in phospho-Akt pro-survival
signaling were abolished by SMase inhibitors. A, Diff-MN9D cells
were treated with 5 ng/mL TNF in the presence or absence of
SMase inhibitors Desipramine (Des 5 μM) or GW4859 (10 μM) and
protein lysates were thereafter harvested for SDS-PAGE and
immunoblot analysis of phospho-Akt (p-Akt) immunoreactivity.
B, Quantification of western blot analysis of phospho-Akt (p-Akt)
relative to total Akt. One-way ANOVA with Tukey’s post-hoc test,
where ** denotes p < 0.01 compared to TNF without inhibitor.
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intermediate cannot be formed from DSBs [34,57].
Missense mutations in SPT long-chain subunit 1 (SPTLC1)
increase its promiscuous activity towards alanine over
serine and result in pathologically elevated DSB levels inthe case of the autosomal dominant hereditary sensory and
autonomic sensory neuropathy type 1 HSAN1 [34,58]; as
evidence of their capacity to induce cytotoxicity, addition of
deoxySa to dorsal root ganglion (DRG) neurons in culture
can be shown to reduce neurite formation and to disrupt
the neuronal cytoskeleton [34]. Given that we observed
similar effects in deoxySa-treated DA neurons, we speculate
that TNF-stimulated de novo synthesis of atypical DSBs
may be a secondary mechanism that contributes to TNF-
dependent toxicity and reduced viability of DA neurons
during inflammatory stress. In fact, neurons may have
heightened vulnerability to cellular disturbances in lipid
metabolism based on the observation that the majority of
GSL lysosomal storage diseases (LSDs) with CNS
involvement result in neuronal death, even though the































































































































































































































Figure 8 TNF treatment induces accumulation of ceramide and several atypical sphingoid bases (DBS) in MN9D dopaminergic (DA)
neuroblastoma cells derived from mouse ventral mesencephalon. MN9D cells were treated with PBS or 5 ng/mL TNF for 24 or 48 hours as
indicated prior to cell harvest for lipid extraction as described in Methods. A, Lipidomic analyses indicate time-dependent accumulation of
ceramide (Cer), sphingomyelin (SM), and hexosylceramide (HexCer) in TNF-treated cells relative to PBS-treated cells. B, Lipidomic analyses also
revealed time-dependent accumulation of sphingosine (So), sphinganine (Sa), sphingosine-phosphate (SoP), sphinganine-phosphate (SaP),
1-deoxysphinganine (1-deoxySa), and 1-desoxymethylsphinganine (1-desoxyMeSa) after treatment with TNF. All values represent group means
+/− SEM, n = 3. One-way ANOVA with Tukey’s post-hoc test; *** denotes p < 0.001 and * denotes p < 0.05 compared to PBS at 48 hrs. N.S.
denotes not significant.





















































































Figure 9 Atypical sphingoid bases generated in response to
TNF exert direct cytotoxic effects on neurally differentiated
MN9D dopaminergic (DA) cells. MN9D cells were plated in 96-well
plates, and were neurally differentiated as described under Methods
and exposed to treatement media alone (without BSA) or to various
doses of 1-deoxysphinganine (1-deoxySa),
1-desoxymethylsphinganine (1-desoxyMeSa), or
1-desoxymethylsphingosine (1-desoxyMeSo) at the concentrations
indicated in a complex with BSA (25 μM) for 48 hours. Cell viability
was measured by the MTS assay described under Methods. All
values represent group means +/− SEM, n = 3–4. One-way ANOVA
with Tukey’s post-hoc, * denotes difference from treatment media
alone (without BSA) at p < 0.05, *** denotes difference from media
alone at p < 0.001.
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endoplasmic reticulum (ER) stress mechanisms in non-
neuronal cells types [40,41] and ER stress has been
implicated as a potentially important pathway inneurodegenerative diseases [60]; however, whether ER
stress is a cause, result, or epiphenomenon in the DA
neuron loss that occurs in PD has not been firmly estab-
lished. ER stress-mediated cell death has been implicated
in PD pathogenesis [42,61], being coupled to the cell
death program in DA cells in response to the toxin para-
quat [43]. Here, we show for the first time that inflamma-
tory signaling through TNF and ceramide induces ER
stress in DA neuron-like cells and that SMase inhibition
attenuates ER stress and prevents TNF-induced cytotox-
icity (as measured independently by MTS and LDH
release assays). ATF6 is a direct target of the ER stress
response [61] and is known to activate transcription of
chaperone proteins [62] to facilitate protein folding and
processing capacity; ATF6 also activates ER-associated
degradation (ERAD) to promote the degradation of
terminally misfolded proteins [63]. Mechanistically,
defective calcium homeostasis, especially increased intra-
cellular Ca2+ release, presumably from the ER, has been
implicated in neuronal cell death in mouse models exhi-
biting increased CNS glucosylsphingosine levels which
can also suppress neuronal outgrowth [49,64,65]. Our
data that BAPTA-AM markedly blocked ceramide-
induced neurotoxicity is consistent with a role for cera-
mide as a disruptor of Ca2+ homeostasis in DA neurons.
Interestingly, a recent study reported that MPTP treat-
ment induced ER stress and decreased AKT phosphoryl-
ation via loss of TRPC1-dependent ER Ca2+ homeostasis
in human dopaminergic neuroblastoma SH-SY5Y cells
[66]. Importantly, signs of TNF pathway activation
[67,68], ER stress [69,70] and reduced levels of AKT
phosphorylation [71] have all been reported in the SNpc
of PD patients. Taken together, these findings support
the idea that disrupted ER Ca2+ homeostasis and com-
promised Akt pathway activation is a common mechanism
by which TNF-dependent inflammation and oxidative
neurotoxins compromise survival of DA neurons and lead
to development of PD-like features.
Many of the genes associated with PD implicate aber-
rant mitochondrial function in disease pathogenesis [72]
and MPTP and rotenone, which are commonly used in
rodents to induce features of parkinsonism, are potent
mitochondrial complex I inhibitors [73]. While compro-
mised mitochondrial function has been strongly impli-
cated in PD pathophysiology [72], to date, compromised
mitochondrial membrane potential in response to inflam-
matory stimuli (in this case TNF and C2-Cer) has never
been demonstrated in DA cells or DA neurons. Our data
demonstrate that TNF and C2-Cer-induced cytotoxicity in
diff-MN9D cells correlates closely with reduced mito-
chondrial membrane potential and treatment with SMase
inhibitors reverses these mitochondrial deficits. Similarly,
in NGF-differentiated PC12 cells, ceramide signaling has






























































































































Figure 10 The atypical sphingoid base 1-deoxySa reduced neuritic branches and outgrowth in primary DA neurons. Primary neuron-glia
cultures from rat ventral mesencephalon were plated in 96-well plates and exposed to treatment media alone without BSA (0) or to
1-deoxysphinganine (1-deoxySa) at the concentrations indicated in a complex with BSA (25 μM) for 48 hours prior to assessing number of branches
per cell, number of processes, and number of outgrowths per cell as well as cell number using Image Xpress high-content imaging analyses.
1-DeoxySa was the only one of the sphingoid bases tested that reduced neurite outgrowth and branching. All values represent group
means +/− SEM, n= 3–4. One-way ANOVA with Tukey’s post-hoc’ * denotes difference from treatment media alone at p< 0.05, and ** denotes p<0.01.






















Figure 11 Proposed model for cellular mechanisms and signaling pathways activated by TNF and ceramide/sphingolipid signaling to
induce neurotoxicity in DA neurons. We propose a model by which TNF/TNFR1-dependent activation of SMases triggers production of
ceramide and other downstream lipid metabolites that promote activation of caspase-8/3 signaling, decreased Akt activation and mitochondrial
membrane potential, and increased endoplasmic reticulum (ER) stress in DA cells.
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ceramide-induced increases in mitochondrial free calcium
were subsequently shown to originate in the ER in a ROS-
independent fashion [75]. Our data showing that BAPTA-
AM buffering of intracellular free calcium ablates
ceramide-induced cytotoxicity in diff-MN9D cells support
this kind of model; however, additional studies are needed
to determine the source of the cellular Ca2+ and/or the
extent to which disrupted ER or mitochondrial Ca2+
homeostasis plays a causative or synergistic role in TNF
or GSL-induced mitochondrial dysfunction in DA neu-
rons [49,64,65].
A role for caspase-dependent apoptotic signaling has
been implicated in the death of DA neurons that occurs
in PD [76,77] and our findings strongly support a role
for caspase 8/caspase 3 signaling as downstream effec-
tors in TNF-dependent death of dopaminergic cells. It
should be noted that we observe distinct differences in
the overall requirement for caspase signaling in TNF-
versus C2-Cer-dependent cytotoxicity in diff-MN9D
cells. One reason for this may be that TNF signaling
generates ceramide in a physiological range which acts
in concert with other TNF receptor-mediated signaling
events to trigger downstream caspase-dependent apop-
totic processes, whereas addition of exogenous C2-Cer
(at concentrations that may not be within a physiological
range) artificially bypasses TNF receptor-mediated
events and exerts toxic effects by targeting other path-
ways in addition to mitochondria and caspase inhibition
and is not sufficient to attenuate cytotoxicity from this
extreme insult. Jurkat T cells require ASMase transloca-
tion to plasma membrane lipid microdomains to elicit
localized ceramide production and eventual apoptotic
cell death [78]. Interestingly, in these cells, ASMase
translocation has been shown to occur via two distinct
mechanisms: a caspase-dependent mechanism utilized
by Fas-L and a previously unrecognized caspase-
independent mechanism elicited by short wave ultravio-
let irradiation (UV-C). Specifically, it was determined
that the caspase-independent mechanism of ASMase
translocation led to cell death of Jurkat cells and that
UV-C treatment of Jurkat cells activates the sphingo-
myelin pathway independent of caspase 8 or in the pres-
ence of a pan-caspase inhibitor. In this study, the
authors note that while ASMase is not a direct target of
caspase 8, surface translocation of ASMase activated by
Fas-L or other TNF superfamily ligands requires min-
imal caspase 8 and FADD activation (~2% activation is
sufficient). In the case of diff-MN9D cells, exogenous
addition of C2-Ceramide bypasses the step of ASMase
translocation to lipid microdomains in the plasma mem-
brane as well as the concomitant activation of caspase
cascades from the signaling complex assembled in
microdomains at the cell membrane that otherwiseoccurs in response to TNFR1 activation, which is likely
to result in toxicity that is caspase-independent. Alterna-
tively, it is possible that exogenous addition of ceramide
is sufficient to elicit caspase independent cell death via
release of mitochondrial apoptogenic factors, but that
engagement of TNFR1 by its ligand TNF leads to
SMase-dependent production of ceramide and caspase-
dependent cell death of diff-MN9D cells. Lastly, Deerberg
and colleagues report that there is a combined requi-
rement of both the ER and mitochondria in the induction
of signaling pathways of ceramide-mediated caspase-
independent programmed cell death in Jurkat cells
[79] and a similar mechanism may be occurring in C2-
Ceramide treated diff-MN9D cells. Collectively, our data
support a model whereby TNF concentrations in the
range that elicit half-maximal cytotoxicity and that
correspond to low TNF receptor 1 (TNFR1) occupancy
activate SMase to initiate downstream signaling by cera-
mide and other sphingolipid metabolites, which trigger
ER stress, decreased mitochondrial membrane potential,
and eventually culminate in the caspase-dependent cyto-
toxic cell death of DA neurons (Figure 11). Support for
this model comes from the multiple studies presented
here in which pharmacological inhibition of SMases to
block ceramide generation during TNF exposure main-
tained mitochondrial membrane potential, markedly atte-
nuated TNF-induced ER stress and caspase signaling and
restored p-Akt levels in DA cells, thereby promoting
significant protection from TNF-induced neurotoxicity.
The histopathophysiological hallmark of Parkinson’s
disease (PD) is the formation of intraneuronal aggrega-
tion and clustering of α-synuclein and ubiquitinated pro-
teins into inclusions commonly referred to as Lewy
bodies (LB) typically found in DA neurons of the sub-
stantia nigra pars compacta (SNpc) in the ventral
midbrain [80]. Notably, several genes known to be
involved in the genetics of Lewy body disease (LBD) or
heritable PD share in common the fact that they im-
pinge on ceramide metabolism [81]. Therefore, ceramide
metabolism has recently received attention as an emer-
ging pathway involved in LBD [82]. For example, heterozy-
gous loss-of-function mutations of the glucocerebrosidase
(GBA) locus have recently been shown to be a potent risk
factor for PD [81,83]. GBA catalyzes the dissolution of glu-
cocerebrosidase to ceramide and glucose. The lysosomal
storage disease Gaucher’s disease (GD) arises from homo-
zygous mutations in GBA, leading to extreme lysosomal ac-
cumulation of GBA substrates and onset of GD symptoms
[84]. Interestingly however, GBA substrates do not signifi-
cantly accumulate in the lysosomes of patients with hetero-
zygous GBA mutations, lending support to the hypothesis
that generally disrupted ceramide metabolism, as opposed
to specific loss of GBA function, may be an initiating factor
in PD [81]. Our data offer a mechanistic link between
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function, apoptotic signaling and neuronal death in dopa-
minergic neurons in response to TNF exposure which may
be of significance in PD but perhaps also in other chronic
neurodegenerative conditions characterized by elevated
levels of TNF and other inflammatory factors. Interestingly,
the ASMase inhibitor desipramine induces specific and
rapid intracellular degradation of ASMase and concomitant
abolishment of enzymatic activity [85]; however, desipra-
mine is a tricyclic antidepressant and its action on neuro-
transmitters seems to be independent of its effects on
ASMase activity. Nevertheless, desipramine has been used
in clinical trials to treat depression in PD patients [86];
these trials were very short-lived however, and the effect of
desipramine on ceramide signaling was not evaluated as an
outcome. Therefore, our data and the data of other groups
associating ceramide biology and metabolism with PD
warrant future studies examining the potential neuropro-
tective effects of inhibition of ASMase or NSMase in ani-
mal models of PD.
In summary, DA neurons in the substantia nigra pars
compacta (SNpc) are preferentially vulnerable to neuroin-
flammatory stimuli and our group previously demonstrated
that chronic inhibition of soluble tumor necrosis factor
(TNF) signaling with dominant-negative TNF inhibitors
attenuated the loss of nigral DA neurons in models of PD.
Our present findings support a molecular pathway by
which TNF-dependent ceramide/sphingolipid signaling
intermediates compromise survival of DA neurons by inhi-
biting neurite outgrowth, inducing ER stress, reducing
mitochondria membrane potential, activating caspase 3-
dependent pro-apoptotic signaling cascades and inhibiting
Akt-dependent pro-survival signaling pathways. Additional
studies are warranted to explore which specific ceramide
metabolites and/or atypical sphingoid bases (or combina-
tions thereof) may represent surrogate biomarkers and/or
novel drug targets for development of neuroprotective
strategies to halt or delay the progressive loss of DA neu-
rons that lead to the disabling motor fluctuations in
patients with PD.Additional files
Additional file 1: Figure S1. Non-diff-MN9D cells are not sensitive to
C2-Cer-induced cell death. AlamarBlue assay performed as per
manufacturer’s instructions. All values represent group means +/− SEM,
n = 3–4. One-way ANOVA, Tukey’s post-hoc test; n.s. denotes no
significance.
Additional file 2: Figure S2. TNF-induced cytotoxicity in diff-MN9D
cells does not require de novo biosynthesis of ceramide. Diff-MN9D cells
were pre-treated with myriocin (Myr, an inhibitor for serine
palmitoyltransferase) or fumonisin B1 (FB1, an inhibitor of ceramide
synthase) for 30 minutes prior to addition of TNF for an additional
48 hours. Cell viability was measured via an MTS assay as described
under Methods. All values represent group means +/− SEM, n =3 - 4.
Two-way ANOVA to test for differences between TNF with inhibitorversus TNF without inhibitor for both Myrocin and Fumonisin B1; there
were no significant differences between No MYR and 10 μM MYR at any
TNF concentration, as determined by a two-way ANOVA. There was
statistically significant TNF-induced death of diff-MN9D cells, as
determined by a Tukey’s post-hoc test following a statistically significant
one-way ANOVA, where ** denotes p < 0.01, *** p < 0.001 for No MYR
conditions relative to vehicle, * denotes p < 0.05 for TNF 10 +No MYR
compared to TNF 30 +No MYR, and ### denotes p < 0.001 for 10 μM
MYR conditions relative to vehicle. There were no significant differences
between No FB1 and 50 μM FB1 at any TNF concentration, as
determined by a two-way ANOVA. There was statistically significant
TNF-induced death of diff-MN9D cells, as determined by a Tukey's
post-hoc test following a statistically significant one-way ANOVA where
* denotes p < 0.05, *** denotes p < 0.001 for No FB1 conditions relative to
vehicle, ** denotes p < 0.01 for TNF 10 +No FB1 compared to TNF
30 +No FB1, and ### denotes p < 0.001 for 50uM FB1 conditions relative
to vehicle, # denotes p < 0.01 for TNF 10 + 50 μM FB1 compared to TNF
30 + 50 μM FB1.
Additional file 3: Figure S3. The atypical sphingoid bases
1-deoxyMeSa and 1-deoxyMeSo did not exert cytotoxicity on primary DA
neurons. Primary neuron-glia cultures from rat ventral mesencephalon
were plated in 96-well plates and exposed to treatment media alone
without BSA (0) or to 1-desoxymethylsphingosine
(1-desoxyMeSo) or 1-desoxymethylsphinganine (1-desoxyMeSa) at the
concentrations indicated in a complex with BSA (25 μM) for 48 hours
prior to assessing number of branches per cell, number of processes, and
number of outgrowths per cell as well as cell number using Image
Xpress high-content imaging analyses. All values represent group means
+/− SEM, n = 3–4. There were no significant effects from treatment with
1-deoxyMeSa and 1-deoxyMeSo as determined by a one-way ANOVA.
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